BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $39
Cullinan Therapeutics Inc CGEM
$16.50
▼ -5.82%
($-1.02)
⬇️ Below Yest. Low
📅 Earnings This Week
Open
$17.52
Prev Close
$17.52
Day Range
$16.14 – $17.52
52W Range
$5.68 – $19.43
Market Cap
$1.01B
Beta
0.01
EPS (TTM)
$-3.72
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-01-08 |
| Shares Out. | 61,460,000 |
| Website | cullinantherapeutics.com/ ↗ |
| Phone | 16174104650 |
| Employees | 109 |
| Net Income | -$49.7M |
| Free Cash Flow | -$178.7M |
| Total Assets | $403.0M |
| Total Liabilities | $36.8M |
| Equity | $366.2M |
About Cullinan Therapeutics Inc
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
Cullinan Therapeutics Inc is a publicly traded company under the ticker symbol CGEM on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
19 analysts (2026-07-01)